3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases

1. A compound of formula (IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof; wherein

X is CR 1 or N;

D is monocyclic aryl; wherein D is substituted with a group E which is selected from —CONH—O—(CR x R y ) p —OR x , and —CONH—O—(CR x R y ) p -[cycloalkyl]-(CR x R y ) p —OR x ; and further D can optionally be substituted with one or more of R z ;

L 2 is —(CR a R b )—;

Cy 2 is substituted or unsubstituted heteroaryl;

each occurrence of R 1 and R 2 may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR a , —S(═O) q —R a , —NR a R b , —C(═Y)—R a , —CR a R b —C(═Y)—R a , —CR a R b —Y—CR a R b R b , —C(═Y)—NR a R b , —NR a R b —C(═Y)—NR a R b , —S(═O) q —NR a R b —, —NR a R b —S(═O) q —NR a R b , —NR a R b —NR a R b , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl;

each occurrence of Y is independently selected from O, S, and NR a ;

each occurrence of R a and R b may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl, or when two R a and/or R b substituents are directly bound to a common atom, they may be joined to form a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR c or S;

each occurrence of R c is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl;

each occurrence of R x and R y is independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —COOR z , —C(O)R z , —C(S)R z , —C(O)NR z R z , —C(O)ONR z R z , —NR z R z , —NR z CONR z R z , —N(R z )SOR z , —N(R z )SO 2 R z , —(═N—N(R z )R z ), —NR z C(O)OR z , —NR z C(O)R z —, —NR x C(S)R y —NR z C(S)NR z R z , —SONR z R z —, —SO 2 NR z R z —, —OR z , —OR z C(O)NR z R z , —OR z C(O)OR z —, —OC(O)R z , —OC(O)NR z R z , —R z NR z C(O)R z , —R z OR z , —R z C(O)OR z , —R z C(O)NR z R z , —R z C(O)R z , —R z OC(O)R z , —SR z , —SOR z , —SO 2 R z , and —ONO 2 , or any two of R x and R y which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR z or S, or (ii) an oxo (═O), thio (═S) or imino (═NR z ); wherein

each occurrence of R z is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and —ONO 2 , or any two of R z which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR ′ (where R ′ is H or alkyl) or S, or (ii) an oxo (═O), thio (═S) or imino (═NR z );

each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8; and

each occurrence of q independently represents 0, 1 or 2,

with the proviso that when Cy 2 is substituted or unsubstituted heteroaryl, each occurrence of R 1 and R 2 is hydrogen, and E is —CONH—O—(CR x R y ) p —OR x , then p is not 2.

2. A compound of claim 1 , wherein

D is

E is selected from —CONH—O—(CR x R y ) p —OR x , and —CONH—O—(CR x R y ) p -[cycloalkyl]-(CR x R y ) p —OR x ; and

X 1 , X 2 and X 3 are independently selected from —CR z or —CR z ═CR z .

3. A compound of claim 1 , wherein Cy 2 is selected from

4. A compound of claim 1 , wherein L 2 is —CH 2 —, —CH(OH)—, —CHF—, —CF 2 —, —CH (CH 3 )— or —C(CH 3 ) 2 —.

5. A compound of formula (IA-I):

or a tautomer, stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof, wherein

-L 2 -Cy 2 is

(where the squiggly line represents the bond to the bicyclic core in formula (IA-I));

each occurrence of R a and R b are independently selected from hydrogen, halogen, and substituted or unsubstituted (C 1-6 ) alkyl, or both together with the carbon atom to which they are attached form a saturated 3 to 6 member cyclic ring which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR e and S (where R e is R z );

Z is selected from CR c , S, O, NR c , R c C═CR c , —N═CR c —, and —R c C═N—;

Z 1 is selected from N, NR c and CR c ;

Z 2 and Z 3 are independently selected from C or N;

R c is absent or selected from hydrogen, hydroxy and halogen;

X is CR 1 or N;

D is monocyclic aryl; wherein D is substituted with a group E which is selected from —CONH—O—(CR x R y ) p —OR x , and —CONH—O—(CR x R y ) p -[cycloalkyl]-(CR x R y ) p —OR x ; and further D can optionally be substituted with one or more of R z ;

each occurrence of R 1 and R 2 may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR a , —S(═O) q —R a , —NR a R b , —C(═Y)—R a , —CR a R b —C(═Y)—R a , —CR a R b —Y—CR a R b R b , —C(═Y)—NR a R b , —NR a R b —C(═Y)—NR a R b , —S(═O) q —NR a R b —, —NR a R b —S(═O) q —NR a R b , —NR a R b —NR a R b , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl;

each occurrence of Y is independently selected from O, S, and NR a ;

each occurrence of R x and R y is independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —COOR z , —C(O)R z , —C(S)R z , —C(O)NR z R z , —C(O)ONR z R z , —NR z R z , —NR z CONR z R z , —N(R z )SOR z , —N(R z )SO 2 R z , —(═N—N(R z )R z ), —NR z C(O)OR z , —NR z C(O)R z —, —NR x C(S)R y —NR z C(S)NR z R z , —SONR z R z —, —SO 2 NR z R z —, —OR z , —OR z C(O)NR z R z , —OR z C(O)OR z —, —OC(O)R z , —OC(O)NR z R z , —R z NR z C(O)R z , —R z OR z , —R z C(O)OR z , —R z C(O)NR z R z , —R z C(O)R z , —R z OC(O)R z , —SR z , —SOR z , —SO 2 R z , and —ONO 2 , or any two of R x and R y which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR z or S, or (ii) an oxo (═O), thio (═S) or imino (═NR z ), wherein

each occurrence of R z is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and —ONO 2 , or any two of R z which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR (where R′ is H or alkyl) or S, or (ii) an oxo (═O), thio (═S) or imino (═NR z );

each occurrence of q independently represents 0, 1 or 2; and

each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8, with the proviso that when each occurrence of R 1 and R 2 is hydrogen, and E is —CONH—O—(CR x R y ) p —OR x , then p is not 2.

6. A compound of formula (IA-I):

or a tautomer, stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof, wherein

D is

L 2 -Cy 2 is

(where the squiggly line represents the bond to the bicyclic core in formula (IA-I));

X is CR 1 or N;

X 1 , X 2 and X 3 are independently selected from —CR z or —CR z ═CR z ;

Z is selected from CR c , S, O, NR c , R c C═CR c , —N═CR c —, and —R c C═N—;

Z 1 is selected from N, NR c and CR c ;

Z 2 and Z 3 are independently selected from C or N;

E is selected from —CONH—O—(CR x R y ) p —OR x , and —CONH—O—(CR x R y ) p -[cycloalkyl]-(CR x R y ) p —OR x ;

each occurrence of R 1 and R 2 may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR a , —S(═O) q —R a , —NR a R b , —C(═Y)—R a , —CR a R b —C(═Y)—R a , —CR a R b —Y—CR a R b R b , —C(═Y)—NR a R b , —NR a R b —C(═Y)—NR a R b , —S(═O) q —NR a R b —, —NR a R b —S(═O) q —NR a R b , —NR a R b —NR a R b , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl;

each occurrence of Y is independently selected from O, S, and NR a ;

each occurrence of R a and R b may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl, or when two R a and/or R b substituents are directly bound to a common atom, they may be joined to form a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR c or S;

each occurrence of R c is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 3-6 cycloalkylalkyl, and substituted or unsubstituted C 3-6 cycloalkenyl;

each occurrence of R x and R y is independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —COOR z , —C(O)R z , —C(S)R z , —C(O)NR z R z , —C(O)ONR z R z , —NR z R z , —NR z CONR z R z , —N(R z )SOR z , —N(R z )SO 2 R z , —(═N—N(R z )R z ), —NR z C(O)OR z , —NR z C(O)R z —, —NR x C(S)R y —NR z C(S)NR z R z , —SONR z R z —, —SO 2 NR z R z —, —OR z , —OR z C(O)NR z R z , —OR z C(O)OR z —, —OC(O)R z , —OC(O)NR z R z , —R z NR z C(O)R z , —R z OR z , —R z C(O)OR z , —R z C(O)NR z R z , —R z C(O)R z , —R z OC(O)R z , —SR z , —SOR z , —SO 2 R z , and —ONO 2 , or any two of R x and R y which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR z or S, or (ii) an oxo (═O), thio (═S) or imino (═NR z ); wherein

each occurrence of R z is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and —ONO 2 , or any two of R z which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR (where R′ is H or alkyl) or S, or (ii) an oxo (═O), thio (═S) or imino (═NR z );

each occurrence of q independently represents 0, 1 or 2;

each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8,

with the proviso that when each occurrence of R 1 and R 2 is hydrogen, and E is —CONH—O—(CR x R y ) p —OR x , then p is not 2.

7. A compound of claim 2 , wherein X 1 and X 2 are CR z and X 3 is —CR z ═CR z .

8. A compound of claim 1 , wherein D is selected from

9. A compound of claim 1 , wherein D is selected from

10. A compound of claim 9 , wherein E is selected from

and R z is selected from hydrogen, halogen or substituted or unsubstituted alkyl.

11. A compound of claim 5 , wherein

each of R a and R b is hydrogen, alkyl or halogen; and

R c is hydrogen or fluoro.

12. A compound of claim 5 , wherein

Z is CR c , N, S, O, —HC═CH— or —N═CH—;

Z 1 is CH or N;

Z 2 is C; and

Z 3 is C or N.

13. A compound of claim 5 , wherein X is N or CR 1 and R 1 is H, substituted or unsubstituted C 1-6 alkyl, NH 2 , OH, CN or CONH 2 .

14. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition of claim 14 , further comprising one or more additional therapeutic agents and mixtures thereof.

16. The pharmaceutical composition of claim 15 , wherein the one or more additional therapeutic agent is an anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.

17. A method of inhibiting the HGF/c-Met kinase signaling pathway in a cell comprising contacting said cell with a compound of claim 1 .

18. A compound selected from

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl acetate,

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl 2-(tert-butoxycarbonylamino)propanoate,

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl 2-aminopropanoate,

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl pivalate,

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl isobutyrate,

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl 2-benzamidoacetate,

2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

ethyl 2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)acetate,

2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

(S)—N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

(R)—N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide,

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl acetate,

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl isobutyrate,

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl pivalate,

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl benzoate,

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)ethyl furan-2-carboxylate,

and pharmaceutically acceptable salts thereof.

19. A compound selected from:

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide,

2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide,

and pharmaceutically acceptable salts thereof.